SCHEMBL19285262

SCHEMBL19285262

COC(=O)[C@@H]1CCc2cc(Cl)ccc21

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.46
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
SRD5A1 P18405 4/20 0.44
SRD5A2 P31213 2/20 0.44
PDE10A Q9Y233 1/20 0.42
MAP4K4 O95819 2/20 0.41
PDE5A O76074 1/20 0.41
TRPV1 Q8NER1 2/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
AKR1C3 P42330 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23670494 1.00 P2RX7 (0.46) P2RX7PDE4APDE4BPDE4CPDE4D
SCHEMBL19469653 1.00 P2RX7 (0.46) P2RX7PDE4APDE4BPDE4CPDE4D
SCHEMBL29552779 1.00 P2RX7 (0.46) P2RX7PDE4APDE4BPDE4CPDE4D
SCHEMBL24542982 0.91 KDM4C (0.42) P2RX7PDE4APDE4BPDE4CPDE4D
SCHEMBL19469643 0.88 HTR2B (0.41) PDE4DPDE10AHTR2AHTR2CHTR2B
SCHEMBL9364487 0.86 AKR1C3 (0.50) HTR2BAKR1C3
SCHEMBL24481808 0.82 PIN1 (0.51) SRD5A1PDE10ATRPV1ALDH1A1
SCHEMBL23552445 0.82 P2RX7 (0.52) P2RX7PDE4APDE4BPDE4CPDE4D
SCHEMBL29610046 0.82 PIN1 (0.51) SRD5A1PDE10ATRPV1ALDH1A1
SCHEMBL1530291 0.82 SRD5A1 (0.44) SRD5A1TRPV1AKR1C3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12091425-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2024-09-17 US disclosed
US-20230052348-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2023-02-16 US disclosed
US-20230052348-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2023-02-16 US disclosed
US-11306107-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2022-04-19 US disclosed
US-20210230189-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2021-07-29 US disclosed
US-20210230189-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2021-07-29 US disclosed
WO-2017147410-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2017-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230189-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 P2RX7 4592/4885PDE4A 4341/4885PDE4B 4334/4885
US-11306107-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 P2RX7 4592/4885PDE4A 4341/4885PDE4B 4334/4885
US-20230052348-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 P2RX7 4592/4885PDE4A 4341/4885PDE4B 4334/4885
US-12091425-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 P2RX7 4592/4885PDE4A 4341/4885PDE4B 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.